ALK-Abelló stock
Price history
+5.93% over the period1 year: from kr 236.00 (November 17, 2025) to kr 250.00 (November 17, 2026), +5.93%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | kr 250.00 |
| October 30, 2026 | kr 248.00 |
| September 30, 2026 | kr 198.40 |
| August 31, 2026 | kr 208.80 |
| July 31, 2026 | kr 222.00 |
| June 30, 2026 | kr 244.20 |
| May 29, 2026 | kr 268.00 |
| April 30, 2026 | kr 238.40 |
| March 31, 2026 | kr 202.20 |
| February 27, 2026 | kr 220.40 |
| January 30, 2026 | kr 207.60 |
| December 30, 2025 | kr 228.60 |
| November 28, 2025 | kr 230.80 |
| November 17, 2025 | kr 236.00 |
At a glance
The company
Develops allergy immunotherapy products, adrenaline treatments, and allergen extracts for respiratory, food, and anaphylaxis allergies across multiple regions
Latest results
Quarter to June 30, 2026 · EPS kr 1.50 (estimate kr 1.60)
TickerLandia's take on ALK-Abelló
- Priced as usual relative to earnings: P/E on the latest fiscal year 46 vs a median of 45 over its last 6 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 41 vs 41 (+0%) in a group of 9.
- Strong point: Earnings stability (84/100 in its group). Weak point: Dividend (40/100).
- “Most upside for analysts” (Denmark): No. 7 of 21.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−9.36% from the 52-week high
Analysts · 6 analysts
Average targetkr 289.67+17.75% vs. price
Buy 6 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: ALK-Abelló
Compared with similar companies: very high earnings stability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage57
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 25.7 57 Forward P/E 33.6 68 P/E (trailing 12 months) 40.7 55 Price/book 7.94 65 Price/sales 8.06 41 Profitabilityhigh66
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 26.9% 65 ROE 21.2% 74 ROA 12.7% 88 Gross margin 68.2% 42 Net margin 19.9% 61 Earnings stabilityvery high84
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 7.4% 84 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthaverage46
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +11.85% 29 Revenue growth (year over year) +17.60% 46 Earnings growth (year over year) +25.00% 64 Financial strengthaverage59
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.43 51 Interest coverage 53.7 71 Current ratio 3.46 54 Debt/equitycounts in reverse: lower means more financial strength 0.06 59 Dividendlow40
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 1 year 30 Dividend yield 0.6% 42 Payout ratio 26.2% 47 Market momentumaverage54
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +4.24% 41 Distance from 200-day average +7.87% 66 Riskaverage54
How much the price swings.
Metric Value Position in group Volatility (60 days) 25.6% 43 Maximum drawdown (12 months) 28.9% 66
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
ALK-Abelló is priced as in the past and in line with similar companies
On the latest fiscal year's earnings (2025), ALK-Abelló's P/E today is 46.3, in line with the median of its last 6 fiscal years (44.6; between 33.8 and 173.2 from 2016 to 2025). ALK-Abelló's P/E (trailing 12 months): 40.7, in line with the median of a group of 9 similar companies (40.7).
Compared with 9 similar companies
| Metric | ALK-Abelló | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 40.7 | Middle | |
| Forward P/E | 33.6 | Middle | |
| Operating margin | 26.9% | Middle | |
| ROE | 21.2% | High | |
| Debt/equity | 0.06 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: ALK-Abelló. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 1.8B
Latest quarter · Q2 2026
Net income
kr 339M
Latest quarter · Q2 2026
Quarterly net margin
18.9%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- kr 55.04B
- P/E
- 40.7
- EPS
- kr 6.10
- Volume
- 97.07K
- Daily trading
- €5.79M
- Dividend yield
- 0.65%
- Last ex-dividend on March 17, 2026
How ALK-Abelló is changing
All resultsRevenue grew 12.6% a year on average over the last 5 years
Operating margin rose from 10.5% to 26.4%
Profits turn into cash: free cash flow equal to 114% of net income
Returns
ALK-Abelló returns with dividends
kr 1,000 invested in ALK-Abelló 5 years ago, on November 17, 2021, would be worth kr 1,585 today with dividends reinvested: +58.51% in total, +9.65% per year. On price alone it would be kr 1,573 (+57.33%).
| Period | ALK-Abelló | kr 1,000 becomes |
|---|---|---|
| 1 month | +5.49% | kr 1,055 |
| 6 months | −2.69% | kr 973 |
| Year to date | +9.36% | kr 1,094 |
| 1 year | +6.73% | kr 1,067 |
| 3 years | +165.83% | kr 2,658 |
| 5 years | +58.51% | kr 1,585 |
| 10 years | +457.12% | kr 5,571 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
ALK-Abelló: technical analysis
ALK-Abelló shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 9.0% below its all-time closing high (kr 270.40, June 12, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 58
- Between 30 and 70
- vs 200-session average
- +7.87%
Active signals
The price is moving in an unusually narrow range compared with the last year.
since November 13, 2026
Trading on November 17, 2026 was 2.4 times the 20-session average.
Support and resistance
Price areas where ALK-Abelló has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancekr 271.20+10.24%2 touches, last on June 12, 2026
- Last pricekr 246.00
- Supportkr 236.47−3.88%3 touches, last on October 8, 2026
- Supportkr 228.80−6.99%4 touches, last on August 20, 2026
- Supportkr 223.60−9.11%2 touches, last on January 7, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 25.6%
- Largest fall in the last year
- −28.88%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
ALK-Abelló: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for ALK-Abelló has been May: +6.10% on average, positive in 18 years out of 27. The weakest has been February: −1.58% on average, positive in 13 years out of 26. November, the current month, has been positive in 14 years out of 26 (+4.17% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +4.15% | +5.41% | 19 of 26 |
| February | −1.58% | −0.56% | 13 of 26 |
| March | +0.87% | −1.51% | 12 of 26 |
| April | +3.79% | +3.89% | 18 of 27 |
| May | +6.10% | +3.29% | 18 of 27 |
| June | −1.36% | −0.82% | 11 of 27 |
| July | −0.23% | +0.51% | 14 of 27 |
| August | +0.47% | −0.94% | 12 of 27 |
| September | +0.38% | −0.57% | 13 of 27 |
| October | −0.67% | −0.37% | 13 of 27 |
| November | +4.17% | +1.32% | 14 of 26 |
| December | +0.37% | −0.56% | 12 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
ALK-Abelló and its competitors
GRAZAX, ACARIZAX, ODACTRA and RAGWITEK are among the allergy immunotherapy tablets that ALK-Abelló offers for grass pollen, house dust mite and ragweed allergies, while its adrenaline autoinjectors and nasal sprays are used for emergency treatment of anaphylaxis. The portfolio also includes vaccines, injections and sublingual drops for respiratory allergies, a biologic for food allergies called ALK 014, the klarify.me patient engagement platform and allergen extracts used in diagnosis.
- Headquarters
- Horsholm, Denmark
- Employees
- 2,773
- Founded
- 1923
- Chief executive
- Peter Halling
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ALK-AbellóALK.B | $8.09B | 26.9% | 40.7 | −2.69% |
| ABIVAXABVX | $7.61B | -6,270.4% | — | −23.78% |
| Bachem HoldingBANB | $6.92B | 21.8% | 39.2 | +2.26% |
| Financière de TubizeTUB | $11.78B | 0.0% | 109.0 | +19.01% |
| CamurusCAMX | $4.36B | 37.4% | 58.5 | +43.18% |
| BioArcticBIOA.B | $2.72B | 19.6% | 262.7 | −6.04% |
Same industry or related industries, similar size. Compare ALK-Abelló with its competitors · Full profile
